Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma

Published:2009-10 Issue:1 Volume:147 Page:89-96
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Barr Paul M.,Fu Pingfu,Lazarus Hillard M.,Horvath Nancy,Gerson Stanton L.,Koc Omer N.,Bahlis Nizar J.,Snell Michael R.,Dowlati Afshin,Cooper Brenda W.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07836.x/fullpdf

Reference36 articles.

1. Proteasome inhibitors: a novel class of potent and effective antitumor agents;Adams;Cancer Research,1999

2. The role of bortezomib in the treatment of lymphoma;Barr;Cancer Investigation,2007

3. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150;Belch;Annals of Oncology,2007

4. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712);Byrd;Blood,2003

5. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation;Cairoli;Haematologica,2004

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

2. Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study;Annals of Hematology;2021-07-31

3. Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?;Journal of Cancer Research and Clinical Oncology;2017-06-17

4. Case Example of Dose Optimization Using Data From Bortezomib Dose-Finding Clinical Trials;Journal of Clinical Oncology;2016-04-20

5. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib;Cancer Medicine;2015-08-26